Lobbying organisation

Apotex Inc.

17 meetings with public office holders, Jul 14, 2025 to May 21, 2026.

127 meetings on record since the registry opened in 2008.

Meetings over time

  • Jul 2025: 6 meetings, with Galen Richardson, Miro Froehlich, Shahad Khalladi, Jessica Fullerton, Mackenzy Metcalfe
  • Aug 2025: 1 meeting, with Neeraj Bhalla
  • Sep 2025: 0 meetings
  • Oct 2025: 0 meetings
  • Nov 2025: 1 meeting, with Shahad Khalladi
  • Dec 2025: 0 meetings
  • Jan 2026: 1 meeting, with Pamela Aung-Thin
  • Feb 2026: 3 meetings, with Yash Nanda, Justine Frame, Sandenga Yeba, Shahad Khalladi, Guillaume Couillard
  • Mar 2026: 1 meeting, with Deepa Murthy, Frances Anne Watt-Gallardo, Kulvinder Vaid
  • Apr 2026: 3 meetings, with Mélanie Joly, Alex Axiotis-Perez, Galen Richardson, Pamela Aung-Thin
  • May 2026: 1 meeting, with Frances Anne Watt-Gallardo, Kulvinder Vaid
Jul 2025peak 6 in a monthMay 2026

Hover or focus a month to see who was met.

What they lobby about

The registry's own subject categories, chosen by the lobbyist on each filing. Each one opens its own page.

Who they met

Liberal5 met · 5 meetings
Not in Arena's member list19 met · 29 meetings
  • Shahad Khalladi
  • Frances Anne Watt-Gallardo
  • Galen Richardson
  • Jessica Fullerton
  • Kulvinder Vaid
  • Mackenzy Metcalfe
  • Miro Froehlich
  • Pamela Aung-Thin
  • Alex Axiotis-Perez
  • Arianne Reza
  • Deepa Murthy
  • Galen Richardson
  • Guillaume Couillard
  • Justine Frame
  • Loris Mirella
  • Neeraj Bhalla
  • Rodrigo Arancibia
  • Sandenga Yeba
  • Yash Nanda

Health Canada (HC) (8) · Immigration, Refugees and Citizenship Canada (IRCC) (5) · Intergovernmental Affairs Secretariat (IGA) (4) · House of Commons (4) · Finance Canada (FIN) (4) · Privy Council Office (PCO) (2)

In their own words

  • Working with the government on an open and inclusive regulatory regime for generic pharmaceuticals that continues to allow the industry to grow in Canada, and discuss with the government how Apotex can work with them to ensure the security and increase the self-sufficiency of Canada’s drug supply, how the government can help ensure access to international markets including by ensuring that company employees based abroad can travel to Canada, and how the government can utilize generic and biosimilar medications to make pharmacare and other drug programs more sustainable.
  • Pharmaceutical policy: Ongoing interactions related to increased and sustainable utilization of cost-saving generic and biosimilar medicines, and a predictable and viable business environment for generic medicines.
  • Domestic pharmaceutical manufacturing: trade, tariffs, and sustainability of domestic manufacturing.

Meetings from the Commissioner of Lobbying of Canada. Canada does not require lobbyists to disclose what they spend, so there is no lobbying budget to report here — only the meetings they filed.